Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Daniel, Peter Prof. Dr. (1) Kammertöns, Thomas Dr. (3) Kieback, Elisa Dr. (2) Kopp, Joachim Dr. (1) Pezzutto, Antonio Prof. Dr. (1) Schlag, Peter M. Prof. Dr. (1) Uckert, Wolfgang Prof. Dr. (5) Willimsky, Gerald Dr. (3) (-) Blankenstein, Thomas Prof. Dr. (14) (-) Bunse, Mario Dr. (1) (-) Leisegang, Matthias Prof. Dr. rer. nat. (2) Bioinformatik der Genregulation (1) Experimentelle Ultrahochfeld-MR (5) Genetik metabolischer und reproduktiver Störungen (3) Genom-Editierung & Krankheitsmodelle (2) Genomics (1) Immunregulation und Krebs (3) Magnetic Resonance (5) Mobile DNA (1) (-) Molekulare Immunologie und Gentherapie (15) Proteom Dynamik (1) RNA Biologie und Posttranscriptionale Regulation (1) Transgenics (2) Translationale Onkologie solider Tumore (1) Zelluläre Neurowissenschaften (2) 1992 (4) 1993 (7) 1994 (5) 1995 (8) 1996 (6) 1997 (9) 1998 (9) 1999 (2) 2000 (8) 2001 (5) 2002 (5) 2003 (9) 2004 (8) 2005 (10) 2006 (1) 2007 (5) (-) 2008 (5) 2009 (2) 2010 (7) (-) 2011 (5) 2012 (6) 2013 (11) 2014 (3) 2015 (3) (-) 2016 (5) 2017 (6) 2018 (5) 2019 (6) 2020 (1) 2021 (4) 2022 (6) 2023 (4) 2024 (2) 15 Ergebnisse: Active Filter: Blankenstein, Thomas Prof. Dr.Bunse, Mario Dr.Leisegang, Matthias Prof. Dr. rer. nat.Molekulare Immunologie und Gentherapie 200820112016 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein 01. November 2011 / Eur J Immunol Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors J. Charo C. Perez C. Buschow A. Jukica M. Czeh T. Blankenstein 15. Januar 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens 01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto 07. April 2016 / Nat Biotechnol Receptor combinations hone T-cell therapy T. Blankenstein 17. Mai 2016 / Immunity Thymus-derived regulatory T cells are positively selected on natural self-antigen through cognate interactions of high functional avidity E. Kieback E. Hilgenberg U. Stervbo V. Lampropoulou P. Shen M. Bunse Y. Jaimes P. Boudinot A. Radbruch U. Klemm A.A. Kühl R. Liblau N. Hoevelmeyer S.M. Anderton W. Uckert S. Fillatreau 22. Juli 2016 / PLoS ONE Interleukin-7 modulates anti-tumor CD8+ T cell responses via its action on host cells K. Deiser D. Stoycheva U. Bank T. Blankenstein T. Schüler 13. Dezember 2011 / Canc Cell Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer K. Anders C. Buschow A. Herrmann A. Milojkovic C. Loddenkemper T. Kammertoens P. Daniel H. Yu J. Charo T. Blankenstein 08. September 2008 / Canc Lett Ablation of TNF or lymphotoxin signaling and the frequency of spontaneous tumors in p53-deficient mice D.V. Kuprash Z. Qin D. Ito S.I. Grivennikov K. Abe L.N. Drutskaya T. Blankenstein S.A. Nedospasov 11. November 2008 / Proc Natl Acad Sci U S A Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas A. Kruschinski A. Moosmann I. Poschke H. Norell M. Chmielewski B. Seliger R. Kiessling T. Blankenstein H. Abken J. Charo Seitennummerierung Aktuelle Seite 1 Seite 2 Nächste Seite Next › Letzte Seite Last »
28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein
01. November 2011 / Eur J Immunol Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors J. Charo C. Perez C. Buschow A. Jukica M. Czeh T. Blankenstein
15. Januar 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto
17. Mai 2016 / Immunity Thymus-derived regulatory T cells are positively selected on natural self-antigen through cognate interactions of high functional avidity E. Kieback E. Hilgenberg U. Stervbo V. Lampropoulou P. Shen M. Bunse Y. Jaimes P. Boudinot A. Radbruch U. Klemm A.A. Kühl R. Liblau N. Hoevelmeyer S.M. Anderton W. Uckert S. Fillatreau
22. Juli 2016 / PLoS ONE Interleukin-7 modulates anti-tumor CD8+ T cell responses via its action on host cells K. Deiser D. Stoycheva U. Bank T. Blankenstein T. Schüler
13. Dezember 2011 / Canc Cell Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer K. Anders C. Buschow A. Herrmann A. Milojkovic C. Loddenkemper T. Kammertoens P. Daniel H. Yu J. Charo T. Blankenstein
08. September 2008 / Canc Lett Ablation of TNF or lymphotoxin signaling and the frequency of spontaneous tumors in p53-deficient mice D.V. Kuprash Z. Qin D. Ito S.I. Grivennikov K. Abe L.N. Drutskaya T. Blankenstein S.A. Nedospasov
11. November 2008 / Proc Natl Acad Sci U S A Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas A. Kruschinski A. Moosmann I. Poschke H. Norell M. Chmielewski B. Seliger R. Kiessling T. Blankenstein H. Abken J. Charo